Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Long-Term Deferred Tax: 2013-2024

Historic Long-Term Deferred Tax for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $71.1 million.

  • Amphastar Pharmaceuticals' Long-Term Deferred Tax rose 33.56% to $71.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.1 million, marking a year-over-year increase of 33.56%. This contributed to the annual value of $71.1 million for FY2024, which is 33.56% up from last year.
  • As of FY2024, Amphastar Pharmaceuticals' Long-Term Deferred Tax stood at $71.1 million, which was up 33.56% from $53.3 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Long-Term Deferred Tax registered a high of $71.1 million during FY2024, and its lowest value of $22.4 million during FY2021.
  • For the 3-year period, Amphastar Pharmaceuticals' Long-Term Deferred Tax averaged around $54.3 million, with its median value being $53.3 million (2023).
  • In the last 5 years, Amphastar Pharmaceuticals' Long-Term Deferred Tax decreased by 10.33% in 2021 and then soared by 72.00% in 2022.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Long-Term Deferred Tax stood at $25.0 million in 2020, then fell by 10.33% to $22.4 million in 2021, then spiked by 72.00% to $38.5 million in 2022, then surged by 38.22% to $53.3 million in 2023, then soared by 33.56% to $71.1 million in 2024.